Advances in Chronic Kidney Disease
Volume 17, Issue 4 , Pages e27-e40 , July 2010

Nocturia and Aging: Diagnosis and Treatment

References 

  1. van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardisation of terminology in nocturia: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:179–183
  2. Mattsson S. Urinary incontinence and nocturia in healthy schoolchildren. Acta Paediatr. 1994;83:950–954
  3. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol. 2006;50:1306–1314discussion 1314–1315
  4. Tikkinen KA, Tammela TL, Huhtala H, et al. Is nocturia equally common among men and women? A population based study in Finland. J Urol. 2006;175:596–600
  5. Ouslander JG, Nasr SZ, Miller M, et al. Arginine vasopressin levels in nursing home residents with nighttime urinary incontinence. J Am Geriatr Soc. 1998;46:1274–1279
  6. Coyne KS, Zhou Z, Bhattacharyya SK, et al. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int. 2003;92:948–954
  7. Asplund R. Mortality in the elderly in relation to nocturnal micturition. BJU Int. 1999;84:297–301
  8. Kobelt G. Health-economic issues in nocturia. BJU Int. 1999;84(Suppl 1):29–32
  9. Guilleminault C, Lin CM, Goncalves MA, et al. A prospective study of nocturia and the quality of life of elderly patients with obstructive sleep apnea or sleep onset insomnia. J Psychosom Res. 2004;56:511–515
  10. Agarwal R, Light RP, Bills JE, et al. Nocturia, nocturnal activity, and nondipping. Hypertension. 2009;54:646–651
  11. Tian Y, Serino R, Verbalis JG. Downregulation of renal vasopressin V2 receptor and aquaporin-2 expression parallels age-associated defects in urine concentration. Am J Physiol Renal Physiol. 2004;287:F797–F805
  12. Kikuchi Y. Participation of atrial natriuretic peptide (hANP) levels and arginine vasopressin (AVP) in aged persons with nocturia [in Japanese]. Nippon Hinyokika Gakkai Zasshi. 1995;86:1651–1659
  13. Ohashi M, Fujio N, Nawata H. High plasma concentrations of human atrial natriuretic polypeptide in aged men. J Clin Endocrinol Metab. 1987;64:81–85
  14. Koopman MG, Koomen GC, Krediet RT, et al. Circadian rhythm of glomerular filtration rate in normal individuals. Clin Sci (Lond). 1989;77:105–111
  15. Asplund R, Aberg H. Diurnal variation in the levels of antidiuretic hormone in the elderly. J Intern Med. 1991;229:131–134
  16. Kawauchi A, Tanaka Y, Soh J, et al. Causes of nocturnal urinary frequency and reasons for its increase with age in healthy older men. J Urol. 2000;163:81–84
  17. Susset JG, Servot-Viguier D, Lamy F, et al. Collagen in 155 human bladders. Invest Urol. 1978;16:204–206
  18. Ouslander JG. Management of overactive bladder. N Engl J Med. 2004;350:786–799
  19. Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci. 1997;314:228–231
  20. Krol E, Rutkowski B, Czarniak P, et al. Early detection of chronic kidney disease: Results of the PolNef study. Am J Nephrol. 2009;29:264–273
  21. Agarwal R. Developing a self-administered CKD symptom assessment instrument. Nephrol Dial Transplant. 2010;25:160–166
  22. Conte G, Dal Canton A, Fuiano G, et al. Mechanism of impaired urinary concentration in chronic primary glomerulonephritis. Kidney Int. 1985;27:792–798
  23. Feinfeld DA, Danovitch GM. Factors affecting urine volume in chronic renal failure. Am J Kidney Dis. 1987;10:231–235
  24. Fukuda M, Motokawa M, Miyagi S, et al. Polynocturia in chronic kidney disease is related to natriuresis rather than to water diuresis. Nephrol Dial Transplant. 2006;21:2172–2177
  25. Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009;169:342–350
  26. McKeigue PM, Reynard JM. Relation of nocturnal polyuria of the elderly to essential hypertension. Lancet. 2000;355:486–488
  27. Yalkut D, Lee LY, Grider J, et al. Mechanism of atrial natriuretic peptide release with increased inspiratory resistance. J Lab Clin Med. 1996;128:322–328
  28. Kaynak H, Kaynak D, Oztura I. Does frequency of nocturnal urination reflect the severity of sleep-disordered breathing?. J Sleep Res. 2004;13:173–176
  29. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–178
  30. Kaye M. Aging, circadian weight change, and nocturia. Nephron Physiol. 2008;109:11–18
  31. Cugini P, Lucia P, Di Palma L, et al. Effect of aging on circadian rhythm of atrial natriuretic peptide, plasma renin activity, and plasma aldosterone. J Gerontol. 1992;47:B214–B219
  32. Mock LL, Parmelee PA, Kutner N, et al. Content validation of symptom-specific nocturia quality-of-life instrument developed in men: Issues expressed by women, as well as men. Urology. 2008;72:736–742
  33. Abraham L, Hareendran A, Mills IW, et al. Development and validation of a quality-of-life measure for men with nocturia. Urology. 2004;63:481–486
  34. Bing MH, Moller LA, Jennum P, et al. Validity and reliability of a questionnaire for evaluating nocturia, nocturnal enuresis and sleep-interruptions in an elderly population. Eur Urol. 2006;49:710–719
  35. Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193–213
  36. Schatzl G, Temml C, Schmidbauer J, et al. Cross-sectional study of nocturia in both sexes: Analysis of a voluntary health screening project. Urology. 2000;56:71–75
  37. Bliwise DL, Foley DJ, Vitiello MV, et al. Nocturia and disturbed sleep in the elderly. Sleep Med. 2009;10:540–548
  38. Kobelt G, Borgstrom F, Mattiasson A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int. 2003;91:190–195
  39. Patel SR, Ayas NT, Malhotra MR, et al. A prospective study of sleep duration and mortality risk in women. Sleep. 2004;27:440–444
  40. Boyle P, Robertson C, Mazzetta C, et al. The relationship between lower urinary tract symptoms and health status: The UREPIK study. BJU Int. 2003;92:575–580
  41. Pollak CP, Perlick D. Sleep problems and institutionalization of the elderly. J Geriatr Psychiatry Neurol. 1991;4:204–210
  42. Ransmayr GN, Holliger S, Schletterer K, et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology. 2008;70:299–303
  43. Goudsmit E, Neijmeijer-Leloux A, Swaab DF. The human hypothalamo-neurohypophyseal system in relation to development, aging and Alzheimer's disease. Prog Brain Res. 1992;93:237–247discussion 247–248
  44. Sakakibara R, Uchiyama T, Liu Z, et al. Nocturnal polyuria with abnormal circadian rhythm of plasma arginine vasopressin in post-stroke patients. Intern Med. 2005;44:281–284
  45. Tikkinen KA, Johnson TM, Tammela TL, et al. Nocturia frequency, bother, and quality of life: How often is too often? A population-based study in Finland. Eur Urol. 2010;57:488–496
  46. Van der Woude PF, Goudsmit E, Wierda M, et al. No vasopressin cell loss in the human hypothalamus in aging and Alzheimer's disease. Neurobiol Aging. 1995;16:11–18
  47. Yoshimura K, Terada N, Matsui Y, et al. Prevalence of and risk factors for nocturia: Analysis of a health screening program. Int J Urol. 2004;11:282–287
  48. Tikkinen KA, Auvinen A, Johnson TM, et al. A systematic evaluation of factors associated with nocturia—The population-based FINNO study. Am J Epidemiol. 2009;170:361–368
  49. Asplund R. Pharmacotherapy for nocturia in the elderly patient. Drugs Aging. 2007;24:325–343
  50. Darowski A, Chambers SA, Chambers DJ. Antidepressants and falls in the elderly. Drugs Aging. 2009;26:381–394
  51. Asplund R, Johansson S, Henriksson S, et al. Nocturia, depression and antidepressant medication. BJU Int. 2005;95:820–823
  52. Cardozo L, Robinson D. Special considerations in premenopausal and postmenopausal women with symptoms of overactive bladder. Urology. 2002;60:64–71discussion 71
  53. Movig KL, Leufkens HG, Belitser SV, et al. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf. 2002;11:271–279
  54. Shiri R, Hakama M, Hakkinen J, et al. The effects of lifestyle factors on the incidence of nocturia. J Urol. 2008;180:2059–2062
  55. Aslan E, Komurcu N, Beji NK, et al. Bladder training and Kegel exercises for women with urinary complaints living in a rest home. Gerontology. 2008;54:224–231
  56. Margel D, Shochat T, Getzler O, et al. Continuous positive airway pressure reduces nocturia in patients with obstructive sleep apnea. Urology. 2006;67:974–977
  57. Drake MJ, Mills IW, Noble JG. Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J Urol. 2004;171:1199–1202
  58. Vaughan CP, Endeshaw Y, Nagamia Z, et al. A multicomponent behavioural and drug intervention for nocturia in elderly men: Rationale and pilot results. BJU Int. 2009;104:69–74
  59. Appell RA, Sand PK. Nocturia: Etiology, diagnosis, and treatment. Neurourol Urodyn. 2008;27:34–39
  60. Simon HU, Malhotra B. The pharmacokinetic profile of fesoterodine: Similarities and differences to tolterodine. Swiss Med Wkly. 2009;139:146–151
  61. Michel MC. Fesoterodine: A novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008;9:1787–1796
  62. Salvatore S, Serati M, Bolis P. Tolterodine for the treatment of overactive bladder. Expert Opin Pharmacother. 2008;9:1249–1255
  63. Wolzt M, Fabrizii V, Dorner GT, et al. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: An open-label single-dose and multiple-dose study. Eur J Clin Pharmacol. 1998;54:367–373
  64. Wilde MI, McTavish D. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs. 1996;52:883–898
  65. Huskey SW, Dean DC, Miller RR, et al. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Dispos. 1995;23:1126–1135
  66. Steiner JF. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet. 1996;30:16–27
  67. Doroshyenko O, Fuhr U. Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48:281–302
  68. Biastre K, Burnakis T. Trospium chloride treatment of overactive bladder. Ann Pharmacother. 2009;43:283–295
  69. Rembratt A, Graugaard-Jensen C, Senderovitz T, et al. Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. Eur J Clin Pharmacol. 2004;60:397–402
  70. Agerso H, Seiding Larsen L, Riis A, et al. Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol. 2004;58:352–358
  71. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol. 2004;172:1021–1025
  72. Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia: An analysis of risk factors for hyponatremia. Neurourol Urodyn. 2006;25:105–109
  73. Weatherall M. The risk of hyponatremia in older adults using desmopressin for nocturia: A systematic review and meta-analysis. Neurourol Urodyn. 2004;23:302–305
  74. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–2398
  75. Johnson TM, Jones K, Williford WO, et al. Changes in nocturia from medical treatment of benign prostatic hyperplasia: Secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol. 2003;170:145–148
  76. Robinson D, Cardozo L, Terpstra G, et al. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int. 2007;100:840–845
  77. Johnson TM, Burrows PK, Kusek JW, et al. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol. 2007;178:2045–2050discussion 2050–2051
  78. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224
  79. Hassouna MM, Siegel SW, Nyeholt AA, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: A multicenter study on efficacy and safety. J Urol. 2000;163:1849–1854
  80. Kessler TM, Danuser H, Schumacher M, et al. Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity?. Neurourol Urodyn. 2005;24:231–236
  81. Fowler FJ, Wennberg JE, Timothy RP, et al. Symptom status and quality of life following prostatectomy. JAMA. 1988;259:3018–3022

PII: S1548-5595(10)00076-5

doi: 10.1053/j.ackd.2010.04.004

Advances in Chronic Kidney Disease
Volume 17, Issue 4 , Pages e27-e40 , July 2010

Article Tools

* Image Usage & Resolution